Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$185.61M+527.55%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas William Burns
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,094
- Beta
- 0.77
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 23.40
Financials
Revenue
$185.61M+527.5%Net Income
$-18.38M-1685.6%EBITDA
$-6.90M-376.0%Free Cash Flow
$12.09M+1225.1%EPS (diluted)
$-0.31-1133.3%Shares Outstanding (diluted)
58.42M+57.8%Operating Expenses
$167.36MCash & Debt
$286.23MReturn of Capital
$2.79MRevenue by Segment (annual)
$236.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $507.44M | $-187.69M | $-3.28 |
| 2024 | $383.48M | $-146.37M | $-2.77 |
| 2023 | $314.71M | $-134.66M | $-2.78 |
| 2022 | $282.86M | $-99.19M | $-2.09 |
| 2021 | $294.01M | $-49.59M | $-1.07 |
| 2020 | $224.96M | $-120.35M | $-2.70 |
| 2019 | $236.98M | $15.42M | $0.41 |
| 2018 | $181.28M | $-12.95M | $-0.37 |
| 2017 | $159.25M | $-92.0K | $-0.00 |
| 2016 | $114.40M | $4.52M | $0.14 |
| 2015 | $71.70M | $-37.24M | $-2.13 |
| 2014 | $45.59M | $-12.13M | $-0.49 |
| 2013 | $20.95M | $-12.64M | $-0.51 |
| 2012 | $2.43M | $-19.33M | $-9.73 |
Valuation
GKOShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-61.29%Social Signal Score
Mentions (3)
- Newszacks.com·11d ago·Positive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
View source ↗ - Newszacks.com·47d ago·Positive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
View source ↗ - Newsbusinesswire.com·48d ago·Neutral
Glaukos Announces Participation in Wells Fargo Healthcare Conference ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for…
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.12 per share
Typical surprise +33.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.14 vs $-0.21beat
- Wed, Apr 29$-0.18 vs $-0.30beat
- Tue, Feb 17$-0.28 vs $-0.22miss
- Wed, Oct 29$-0.16 vs $-0.27beat
- Wed, Jul 30$-0.24 vs $-0.26beat
- Wed, Apr 30$-0.22 vs $-0.33beat
Estimates and results for GKOS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GKOS officers and directors.
- Bought
- —
- Sold
- $29.2m
0 trades
34 trades
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
- Navratil Tomassold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GKOS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.